VIP and infection: VIPhyb-treated and VIP-KO mice had less inflammation and tissue damage in the liver, with fewer intranuclear viral inclusions, fewer inflammatory leukocytes, less necrosis, and fewer CMV-infected giant cells for 3–10 days after mCMV infection compared with PBS-treated WT mice.